Year in Review

OUTREACH Primary Analysis and Patient-Reported Outcomes
Dr Jeremy Abramson reviews data from the primary analysis of the OUTREACH study in addition to patient-reported outcomes, highlighting the potential for liso-cel utilization in the outpatient and community settings. Read More ›

OUTREACH study evaluating liso-cel in patients with R/R LBCL after ≥2 lines of therapy deemed outpatient monitoring feasible with potential cost savings. Read More ›

Results from the OUTREACH study demonstrate that HR-QoL was either improved or maintained from baseline in most patients with R/R LBCL who received liso-cel after ≥2 lines of therapy. Read More ›

Results from the phase 1 study of CTX110 highlighted the potential for immediate “off-the-shelf” availability of CAR-T therapy with demonstrated clinical benefits in R/R LBCL. Read More ›

A real-world analysis of patients with R/R LBCL who experienced relapse or progression following CAR-T therapy found that approximately 20% achieved long-term survival. Read More ›

A multicenter, retrospective analysis evaluating survival outcomes with CAR-T reported median progression-free survival and median overall survival in double-hit and double-expressor lymphomas mirror data reported for patients with DLBCL. Read More ›

ZUMA-7 Subsequent Therapies and Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity
Dr Jeremy Abramson examines outcomes for patients in ZUMA-7 receiving subsequent treatment and real-world outcomes of axi-cel for LBCL by race and ethnicity, highlighting the need for better equity in access to CAR-T therapy. Read More ›

Analysis of MTV and clinical outcomes in patients with relapsed or refractory LBCL suggests that MTV is a more accurate and sensitive measure of tumor burden versus sum of product diameters. Read More ›

Analysis of patients in ZUMA-7 who necessitated further therapy revealed that re-treatment with CAR-T therapy may be viable after an initial response in the 2L setting. Read More ›

Real-world analysis of outcomes with axi-cel in patients with LBCL by race and ethnicity revealed favorable response rates, with lower response rates observed in African-American patients. Read More ›

Page 1 of 9